© 2005 Oxford University Press
ARTICLE |
Baseline Chest Radiograph for Lung Cancer Detection in the Randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
for the PLCO Project Team
Affiliations of authors: Hubert H. Humphrey Cancer Center, North Memorial Medical Center, Robbinsdale, MN (MMO); Biometry Research Group (PMM, PH, DLL, PCP), Early Detection Research Group (JKG), Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD; Mountain States Tumor Institute, St. Luke's Regional Medical Center, Boise, ID (TMB); Marshfield Clinic Research Foundation, Marshfield, WI (WH); Henry Ford Health System, Detroit, MI (PAK); Environmental and Occupational Health Studies Section, University of Minnesota, Minneapolis, MN (JC); Information Management Systems, Inc., Rockville, MD (TLR, SDW); Westat, Rockville, MD (SP)
Correspondence to: Martin M. Oken, MD, Hubert H. Humphrey Cancer Center, North Memorial Medical Center, 3300 Oakdale Ave. N, Plaza 100, Robbinsdale, MN 55422 (e-mail: martin.oken{at}northmemorial.com).
Background: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was initiated in 1992 to examine cause-specific mortality reduction from screening for these four cancers in men and women. We report lung cancer detection results of the baseline screening round. Methods: Of the 154 942 participants enrolled, who were aged 55–74 years with no history of PLCO cancers, 77 465 were randomly assigned to the intervention arm. Current or former smokers and never smokers in this arm received an initial single-view posterior-anterior chest radiograph. Results: In the initial screen, 5991 (8.9%, 95% confidence interval [CI] = 8.7% to 9.2%) of radiographs were suspicious for lung cancer: 8.2% (95% CI = 7.9% to 8.5%) for women and 9.6% (95% CI = 9.3% to 10.0%) for men. Rates were highest for older age groups and for smokers. Among those 5991 participants with a positive screen, 206 (3.4%, 95% CI = 3.0% to 3.9%) underwent biopsy examination, 126 (61.2%, 95% CI = 54.5% to 67.8%) of whom were diagnosed with lung cancer within 12 months of the screen (59 in women and 67 in men). The positive predictive value was 2.1% (95% CI = 1.7% to 2.5%), and 1.9 lung cancers were detected per 1000 screens. Among these cancers, 44% (95% CI = 35% to 52%) were stage I non–small-cell lung cancer. High rates of lung cancer were found in current smokers (6.3 per 1000 screens) and in former smokers who had smoked within the past 15 years (4.9 per 1000 screens). The lung cancer detection rate among never smokers was 0.4 per 1000 screens; this group accounted for 11% (95% CI = 5.6% to 16.6%) of the cancers identified. Conclusions: In the baseline screen, nearly half the cancers were stage I. Whether this experience results in a reduction in lung cancer mortality is yet to be seen.
CiteULike 
Connotea 
Del.icio.us What's this?
Find additional patient-related information at:
This article has been cited by other articles:
|
|
 |
|
  M. Infante, S. Cavuto, F. R. Lutman, G. Brambilla, G. Chiesa, G. Ceresoli, E. Passera, E. Angeli, M. Chiarenza, G. Aranzulla, et al. A Randomized Study of Lung Cancer Screening with Spiral Computed Tomography: Three-year Results from the DANTE Trial Am. J. Respir. Crit. Care Med., September 1, 2009; 180(5): 445 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Ghosal, P Kloer, and K E Lewis A review of novel biological tools used in screening for the early detection of lung cancer Postgrad. Med. J., July 1, 2009; 85(1005): 358 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Y. Yu, P. F. Pinsky, N. E. Caporaso, N. Chatterjee, M. Baumgarten, P. Langenberg, J. P. Furuno, Q. Lan, and E. A. Engels Lung Cancer Risk Following Detection of Pulmonary Scarring by Chest Radiography in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Arch Intern Med, November 24, 2008; 168(21): 2326 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. I. Henschke and D. F. Yankelevitz CT Screening for Lung Cancer: Update 2007 Oncologist, January 1, 2008; 13(1): 65 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Schnoll, E. P. Wileyto, R. Hornik, J. Schiller, and C. Lerman Spiral Computed Tomography and Lung Cancer: Science, the Media, and Public Opinion J. Clin. Oncol., December 20, 2007; 25(36): 5695 - 5697. [Full Text] [PDF]
|
|
|
|
|
|
H. G. Welch, S. Woloshin, L. M. Schwartz, L. Gordis, P. C. Gotzsche, R. Harris, B. S. Kramer, and D. F. Ransohoff Overstating the Evidence for Lung Cancer Screening: The International Early Lung Cancer Action Program (I-ELCAP) Study Arch Intern Med, November 26, 2007; 167(21): 2289 - 2295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Tammemagi, M. T. Freedman, T. R. Church, M. M. Oken, W. G. Hocking, P. A. Kvale, P. Hu, T. L. Riley, L. R. Ragard, P. C. Prorok, et al. Factors Associated with Human Small Aggressive Non Small Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2082 - 2089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. F. Gareen Noncompliance in cancer screening trials Clinical Trials, August 1, 2007; 4(4): 341 - 349. [Abstract] [PDF]
|
|
|
|
 |
|
 P. F. Pinsky, M. Freedman, P. Kvale, M. Oken, N. Caporaso, and J. Gohagan Abnormalities on chest radiograph reported in subjects in a cancer screening trial. Chest, September 1, 2006; 130(3): 688 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hunt, M. Siva, R. Southon, and T. Treasure Does lung cancer screening with chest X-ray improve disease-free survival? Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 483 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|